Merck announced Tuesday that it has completed its multibillion-dollar tender offer for Idenix Pharmaceuticals, Inc.The Whitehouse Station-based drugmaker said approximately 82.5 percent of Idenix shares were tendered at the purchase price of $24.50 per share. That means Merck will be able to formally complete the acquisition of the Massachusetts-based company Tuesday.
RELATED: Merck to acquire Mass. pharma company for nearly $4B
RELATED: Merck begins tender offer to acquire Idenix for $4B
The purchase price values Idenix at approximately $3.85 billion.
Upon completion of the deal, Idenix will become a wholly owned subsidiary of Merck, and its common stock will no longer be traded.
ALSO ON NJBIZ:
Two top Roseland executives to leave Mack-Cali
Hartz sells Secaucus office building for $69M
Onyx signs leases with Sony Music, two others